Utilization of an Outpatient Integrated Infusion Suite to Decrease Length of Stay, Increase Revenue, and Improve Patient Experience for Elective Chemotherapy Admissions All patients who presented to ...

History of thrombosis and hematologic disease were identified as independent predictors of new thrombotic events among persistently aPL-positive patients.

For older adults with incidentally detected splenomegaly, a very large spleen volume predicts a substantial risk for ...

According to results from a recent retrospective study, patients previously diagnosed with a hematologic malignancy were found to be at a higher risk of developing head and neck cancers compared with ...

Patients with hematologic malignancies are at high risk of thrombotic or hemorrhagic complications. The incidence of these events is greatly variable and is influenced by many factors, including the ...

Please provide your email address to receive an email when new articles are posted on . Nearly one in six patients with hematologic disorders had a negative COVID-19 vaccination-related antibody ...

Please provide your email address to receive an email when new articles are posted on . Pancytopenia occurred in more than 13% of patients with systemic lupus erythematosus receiving immune checkpoint ...

We investigated the incidence of non-hematologic cancer in a cohort of locally dwelling individuals with newly identified high-count MBL compared with two control cohorts and a cohort of patients with ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma. One of the prominent gaps in ...

While recent advances in hematology are exciting, they open the door to more questions. While exciting advances have led to chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint ...